| Patient | Billie Holiday |
|---|---|
| Date of birth | 1993-04-07 |
| Identifiers | MRN HR-ML010-SYN; SSN (made up) 000-10-4472 |
| Document date | 2026-11-01 |
| Author | Constance Mayfield, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Establishing primary care five weeks after release from custody: medication for opioid use disorder, overdose prevention, alcohol care, liver and infection screening, and depression and safety screening. Concerns: She wants to stay off heroin and keep singing, and is afraid of losing her tolerance and overdosing; She wants to drink less, especially around shows; She wants her records kept private and to be treated without judgment. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Buprenorphine 8 mg and naloxone 2 mg sublingual film: half a film (4 mg) on day 1, then one film (8 mg) under the tongue daily | One film under the tongue daily after a 4 mg first dose | Sublingual route | 2026-04-20 to 2026-04-27 | completed | S |
| Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once daily | Two films under the tongue once daily | Sublingual route | 2026-04-27 | active | S |
| Naloxone 4 mg nasal spray, one spray in one nostril for a suspected opioid overdose; may repeat every 2 to 3 minutes in alternating nostrils; call 911 | One spray (4 mg) in one nostril for suspected overdose; repeat every 2 to 3 minutes if there is no response | Nasal route | 2026-04-20 | active | S |
| Acamprosate 333 mg delayed-release oral tablet, two tablets (666 mg) by mouth three times daily | Two tablets by mouth three times daily | Oral route | 2026-04-27 | active | S |
| Thiamine 100 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-04-20 to 2026-10-19 | completed | S |
| Amoxicillin 500 mg oral capsule, one capsule by mouth three times daily for seven days | One capsule by mouth three times daily for seven days | Oral route | 2026-09-21 to 2026-09-28 | completed | S |
| Ibuprofen 400 mg oral tablet, one tablet by mouth every 6 to 8 hours with food as needed for tooth pain, for up to five days | One tablet by mouth every 6 to 8 hours with food as needed, up to five days | Oral route | 2026-09-21 to 2026-09-26 | completed | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 8 hours as needed for tooth pain, no more than 3,000 mg a day, for up to five days | Two tablets by mouth every 8 hours as needed, up to 3,000 mg a day | Oral route | 2026-09-21 to 2026-09-26 | completed | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Advance care planning conversation, about 16 minutes | 2026-08-31 to 2026-08-31 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2026-04-20 | Tdap vaccine | completed | S |
| 2026-04-20 | Hepatitis B vaccine (HepB-CpG), dose 1 of 2 | completed | S |
| 2026-04-20 | Hepatitis A vaccine, adult, dose 1 of 2 | completed | S |
| 2026-04-20 | Pneumococcal conjugate vaccine PCV20 | completed | S |
| 2026-05-26 | Hepatitis B vaccine (HepB-CpG), dose 2 of 2 | completed | S |
| 2026-10-19 | Hepatitis A vaccine, adult, dose 2 of 2 | completed | S |
| 2026-10-19 | Influenza vaccine, 2026-2027 season | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| about 1943 | Heroin use from the early 1940s, becoming a severe addiction in the late 1940s; sought treatment for it at least once | D (CLM-0003, CLM-0005) |
| October 1945 | Heavier drinking and increased drug use after her mother's death | D (CLM-0002) |
| March 16, 1948 | Federal custody after a narcotics possession conviction, about ten months with enforced abstinence; released early | D (CLM-0004) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| mother | Died in 1945; cause not recorded in the cited source | D (CLM-0002) |
| Concern | Status | Evidence |
|---|---|---|
| She wants to stay off heroin and keep singing, and is afraid of losing her tolerance and overdosing | active | S |
| She wants to drink less, especially around shows | active | S |
| She wants her records kept private and to be treated without judgment | active | S |
Most recent measures: Hemoglobin [Mass/volume] in Blood 12.9 on 2026-10-19; MCV [Entitic mean volume] in Red Blood Cells by Automated count 95 on 2026-10-19; Platelets [#/volume] in Blood by Automated count 248 on 2026-10-19; Sodium [Moles/volume] in Serum or Plasma 138 on 2026-04-20; Potassium [Moles/volume] in Serum or Plasma 4 on 2026-04-20; Creatinine [Mass/volume] in Serum or Plasma 0.72 on 2026-04-20; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 113 on 2026-04-20; Glucose [Mass/volume] in Serum or Plasma 88 on 2026-04-20; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 30 on 2026-10-19; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 26 on 2026-10-19; Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma 34 on 2026-10-19; Albumin [Mass/volume] in Serum or Plasma 4 on 2026-04-20; Bilirubin.total [Mass/volume] in Serum or Plasma 0.7 on 2026-04-20; Hepatitis C virus Ab Signal/Cutoff in Serum or Plasma by Immunoassay 0.09 on 2026-04-20; Hepatitis B virus surface Ab [Units/volume] in Serum 3 on 2026-04-20; Phosphatidylethanol [Mass/volume] in Blood 22 on 2026-10-19; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 4 on 2026-10-19; Total score [AUDIT-C] 3 on 2026-08-31; Total score [DAST-10] 7 on 2026-04-20 [S]
Strengths and supports: Supports: musicians she has worked with for years, a close friend who has agreed to carry naloxone, and a peer recovery coach; her music is her strongest source of purpose [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Opioid use disorder (heroin), severe; in early remission in a controlled environment at intake, five weeks after release from custody; on buprenorphine; synthetic modern episode linked to her documented heroin use | active | confirmed | F11.20 | S — Synthetic modern coding of the documented heroin addiction; language is person-first, and the code does not change with a return to use. |
| Alcohol use disorder, moderate; synthetic modern episode linked to her documented heavier drinking after her mother's death | active | confirmed | F10.20 | S — Synthetic modern coding of the documented drinking; the liver disease reported in her last year is not coded, because it was documented long after the episode. |
| Acute periapical abscess of the lower right first molar with localized swelling, treated with an antibiotic and dental drainage; resolved | resolved | confirmed | K04.7 | S — Synthetic acute dental infection; not a historical claim. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-04-20 | Hemoglobin [Mass/volume] in Blood | 12.4 | g/dL | 11.6-15 g/dL | Normal | S |
| 2026-04-20 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 101 | fL | 80-100 fL | High | S |
| 2026-04-20 | Platelets [#/volume] in Blood by Automated count | 236 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-04-20 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-04-20 | Potassium [Moles/volume] in Serum or Plasma | 4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-04-20 | Creatinine [Mass/volume] in Serum or Plasma | 0.72 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-04-20 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 113 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-04-20 | Glucose [Mass/volume] in Serum or Plasma | 88 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-04-20 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 52 | U/L | 10-40 U/L | High | S |
| 2026-04-20 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 38 | U/L | 7-56 U/L | Normal | S |
| 2026-04-20 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 84 | U/L | 5-40 U/L | High | S |
| 2026-04-20 | Albumin [Mass/volume] in Serum or Plasma | 4 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-04-20 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.7 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-04-20 | Hepatitis C virus Ab Signal/Cutoff in Serum or Plasma by Immunoassay | 0.09 | {s_co_ratio} | Below 1.00 is nonreactive | Normal | S |
| 2026-04-20 | Hepatitis B virus surface Ab [Units/volume] in Serum | 3 | m[IU]/mL | >=10 m[IU]/mL | Low | S |
| 2026-04-20 | Phosphatidylethanol [Mass/volume] in Blood | 312 | ng/mL | Below 20 ng/mL: abstinence or light drinking; 20 to 199: significant drinking; 200 or more: heavy drinking | High | S |
| 2026-04-20 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 9 | {score} | S | ||
| 2026-04-20 | Total score [AUDIT-C] | 8 | {score} | S | ||
| 2026-04-20 | Total score [DAST-10] | 7 | {score} | S | ||
| 2026-05-26 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 38 | U/L | 10-40 U/L | Normal | S |
| 2026-05-26 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 30 | U/L | 7-56 U/L | Normal | S |
| 2026-05-26 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 52 | U/L | 5-40 U/L | High | S |
| 2026-05-26 | Phosphatidylethanol [Mass/volume] in Blood | 96 | ng/mL | Below 20 ng/mL: abstinence or light drinking; 20 to 199: significant drinking; 200 or more: heavy drinking | High | S |
| 2026-05-26 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | S | ||
| 2026-07-20 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 44 | U/L | 10-40 U/L | High | S |
| 2026-07-20 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 33 | U/L | 7-56 U/L | Normal | S |
| 2026-07-20 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 61 | U/L | 5-40 U/L | High | S |
| 2026-07-20 | Phosphatidylethanol [Mass/volume] in Blood | 164 | ng/mL | Below 20 ng/mL: abstinence or light drinking; 20 to 199: significant drinking; 200 or more: heavy drinking | High | S |
| 2026-07-20 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 11 | {score} | S | ||
| 2026-08-31 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 2026-08-31 | Total score [AUDIT-C] | 3 | {score} | S | ||
| 2026-10-19 | Hemoglobin [Mass/volume] in Blood | 12.9 | g/dL | 11.6-15 g/dL | Normal | S |
| 2026-10-19 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 95 | fL | 80-100 fL | Normal | S |
| 2026-10-19 | Platelets [#/volume] in Blood by Automated count | 248 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-10-19 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 30 | U/L | 10-40 U/L | Normal | S |
| 2026-10-19 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 | U/L | 7-56 U/L | Normal | S |
| 2026-10-19 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 34 | U/L | 5-40 U/L | Normal | S |
| 2026-10-19 | Phosphatidylethanol [Mass/volume] in Blood | 22 | ng/mL | Below 20 ng/mL: abstinence or light drinking; 20 to 199: significant drinking; 200 or more: heavy drinking | High | S |
| 2026-10-19 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-04-20 | Body height | 165 | cm | S |
| 2026-04-20 | Body weight | 68 | kg | S |
| 2026-04-20 | Body mass index (BMI) [Ratio] | 25 | kg/m2 | S |
| 2026-04-20 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-04-20 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-04-20 | Heart rate | 84 | /min | S |
| 2026-04-20 | Respiratory rate | 16 | /min | S |
| 2026-04-20 | Body temperature | 36.8 | Cel | S |
| 2026-04-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-04-27 | Body height | 165 | cm | S |
| 2026-04-27 | Body weight | 68.2 | kg | S |
| 2026-04-27 | Body mass index (BMI) [Ratio] | 25.1 | kg/m2 | S |
| 2026-04-27 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-04-27 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-04-27 | Heart rate | 78 | /min | S |
| 2026-04-27 | Respiratory rate | 14 | /min | S |
| 2026-04-27 | Body temperature | 36.7 | Cel | S |
| 2026-04-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-05-26 | Body height | 165 | cm | S |
| 2026-05-26 | Body weight | 68.6 | kg | S |
| 2026-05-26 | Body mass index (BMI) [Ratio] | 25.2 | kg/m2 | S |
| 2026-05-26 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-05-26 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-05-26 | Heart rate | 74 | /min | S |
| 2026-05-26 | Respiratory rate | 14 | /min | S |
| 2026-05-26 | Body temperature | 36.6 | Cel | S |
| 2026-05-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-07-20 | Body height | 165 | cm | S |
| 2026-07-20 | Body weight | 67.4 | kg | S |
| 2026-07-20 | Body mass index (BMI) [Ratio] | 24.8 | kg/m2 | S |
| 2026-07-20 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-07-20 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 2026-07-20 | Heart rate | 86 | /min | S |
| 2026-07-20 | Respiratory rate | 16 | /min | S |
| 2026-07-20 | Body temperature | 36.8 | Cel | S |
| 2026-07-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-10-19 | Body height | 165 | cm | S |
| 2026-10-19 | Body weight | 69 | kg | S |
| 2026-10-19 | Body mass index (BMI) [Ratio] | 25.3 | kg/m2 | S |
| 2026-10-19 | Systolic blood pressure | 116 | mm[Hg] | S |
| 2026-10-19 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-10-19 | Heart rate | 72 | /min | S |
| 2026-10-19 | Respiratory rate | 14 | /min | S |
| 2026-10-19 | Body temperature | 36.6 | Cel | S |
| 2026-10-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-08-31 | Body height | 165 | cm | S |
| 2026-08-31 | Body weight | 68.8 | kg | S |
| 2026-08-31 | Body mass index (BMI) [Ratio] | 25.3 | kg/m2 | S |
| 2026-08-31 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-08-31 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-08-31 | Heart rate | 74 | /min | S |
| 2026-08-31 | Respiratory rate | 14 | /min | S |
| 2026-08-31 | Body temperature | 36.7 | Cel | S |
| 2026-08-31 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-09-21 | Body height | 165 | cm | S |
| 2026-09-21 | Body weight | 68.4 | kg | S |
| 2026-09-21 | Body mass index (BMI) [Ratio] | 25.1 | kg/m2 | S |
| 2026-09-21 | Systolic blood pressure | 130 | mm[Hg] | S |
| 2026-09-21 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 2026-09-21 | Heart rate | 92 | /min | S |
| 2026-09-21 | Respiratory rate | 16 | /min | S |
| 2026-09-21 | Body temperature | 37.6 | Cel | S |
| 2026-09-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-04-20 | Establishing primary care five weeks after release from custody: medication for opioid use disorder, overdose prevention, alcohol care, liver and infection screening, and depression and safety screening | finished | S |
| 2026-04-27 | One-week buprenorphine check and addiction medicine consultation | finished | S |
| 2026-05-26 | Five-week recovery review and second hepatitis B vaccine | finished | S |
| 2026-07-20 | Three-month review after a return to opioid use: adjusting the recovery plan | finished | S |
| 2026-10-19 | Six-month recovery, alcohol, liver, and mood review | finished | S |
| 2026-08-31 | Periodic adult preventive visit | finished | S |
| 2026-09-21 | Same-day sick visit for a dental abscess | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Buprenorphine with naloxone started in primary care at a low first dose, then 16 mg daily, continued through any return to use; naloxone, overdose education, never using alone, and fentanyl test strips | completed | GL-ASAM-OUD-2020, GL-SAMHSA-MOUD, GL-SUD-2021 | S |
| Addiction medicine consultation to confirm the medication plan, choose a medicine for alcohol use disorder that can be used with buprenorphine, and set the monitoring plan | completed | GL-ASAM-OUD-2020, GL-SUD-2021 | S |
| Alcohol care: acamprosate, thiamine, brief counseling and goals she chooses, and PEth at each check to follow drinking without relying on memory | completed | GL-SUD-2021, GL-SAMHSA-MOUD | S |
| Liver and infection screening: liver tests and FIB-4 at intake and six months, hepatitis C antibody, hepatitis B triple panel, and HIV test, with hepatitis A and B vaccines for a person who is not immune | completed | GL-AASLD-ALD-2019, GL-AASLD-NIT-2025, GL-CDC-HBV-2023, GL-USPSTF-HCV-2020, GL-USPSTF-HIV-2019 | S |
| Depression screening with the PHQ-9 at each recovery visit, a structured safety assessment with a written safety plan and the 988 Suicide & Crisis Lifeline, and safety review at every visit | completed | GL-CMID-2026, GL-USPSTF-DEP-2023, GL-SUICIDE-2024 | S |
| Integrated, trauma-informed recovery plan: weekly counseling, a peer recovery coach, confidentiality she controls, and a written plan for touring, without requiring recovery to be perfect or linear | completed | GL-SUD-2021, GL-SAMHSA-MOUD | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Stay on buprenorphine without interruption through six months, including through any return to use | 2026-10-19 | completed | Taking buprenorphine 16 mg daily at six months; a three-day gap during a tour was followed by a brief return to use and an immediate restart, with no overdose | S |
| Naloxone at home and in her bag, and a friend trained to use it, by the one-week visit | 2026-04-27 | completed | Two naloxone two-packs dispensed; her friend trained | S |
| Reduce drinking to PEth below 20 ng/mL, or to the level she chooses, by six months | 2026-10-19 | completed | PEth 22 ng/mL from 312; occasional light drinking, which she chose | S |
| Hepatitis A and B vaccine series completed by six months | 2026-10-19 | completed | Hepatitis B doses at intake and five weeks; hepatitis A doses at intake and six months | S |
| PHQ-9 score below 5 by six months | 2026-10-19 | completed | PHQ-9 4 | S |
Structured synthetic safety assessment on 2026-04-20: current ideation absent, intent absent, plan absent. Outpatient care. Overdose risk is high in the weeks after release because tolerance has fallen: naloxone for her and her friend, never using alone, testing any drug supply with fentanyl test strips, and buprenorphine started today. The 988 Suicide & Crisis Lifeline was given and saved in her phone, and a written safety plan was made with her. Safety reviewed at every visit [S]